National Beverage Corp. vs Smith & Nephew plc — how do they compare? National Beverage Corp. trades at $31.95 (market cap $2.89B), while Smith & Nephew plc trades at $31.44 (market cap $12.81B). The key difference: Smith & Nephew plc is far larger — about 4.4× National Beverage Corp.'s market cap, and Smith & Nephew plc pays a 2.54% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.
| FIZZ | SNN | |
|---|---|---|
Market Cap | $2.89B | $12.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $47.69 | $38.70 |
52-Week Low | $30.85 | $28.73 |
Enterprise Value | $2.60B | $15.58B |
Dividend Yield | — | 2.54% |
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $32.09, up 3.78% on the day, but the stock faces bearish technical signals and mixed earnings results, with three of the last four quarters missing EPS estimates. The company maintains solid profitability with a 15.56% net income margin and a 34.03% ROE, while a recent special dividend of $3.25 per share reflects shareholder returns. However, revenue has stagnated around $1.2 billion annually, and analyst sentiment is cautious, with 50% of coverage recommending Sell.
The outlook for FIZZ is clouded by stalled growth and competitive pressures, particularly for its LaCroix brand. While valuation multiples like a P/E of 15.73 appear reasonable, the lack of revenue catalysts and bearish technical trends suggest limited near-term upside. Key risks include declining volumes and consumer weakness, requiring investors to weigh dividend returns against fundamental headwinds.
Smith & Nephew (SNN) trades at $31.41, up 5.28% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $5.8B in 2024 to $6.2B projected for 2025 and net income margin expanding to 10.14%. Recent product launches in robotics and wound care, plus a $500M share buyback, highlight strategic execution. Analyst consensus is mixed with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility where two of the last four quarters missed expectations.
Outlook: SNN's recovery trajectory and product innovation support long-term growth, but investor patience is needed due to earnings inconsistency and moderate debt levels. Key risks include competitive pressures in medtech and execution on guidance. The stock presents a value opportunity if operational improvements continue, trading at reasonable valuations (P/E 21.5, P/S 2.18) versus sector peers.
Trailing returns across standard periods
Latest headlines on both assets
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →